Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 5)¹

Alimera Sciences, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

016259202

(CUSIP Number)

Adam Morgan

Velan Capital Investment Management LP

100 North Main Street, Suite 301

Alpharetta, Georgia 30009

(646) 844-0030

Ryan Nebel

Olshan Frome Wolosky LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

September 16, 2024

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The following constitutes Amendment No. 5 to the Schedule 13D filed by the undersigned (“Amendment No. 5”). This Amendment No. 5 amends the Schedule 13D as specifically set forth herein.

Item 4 is hereby amended to add the following:

On June 21, 2024, the Issuer entered into an Agreement and Plan of Merger (the “Merger Agreement”) with ANI Pharmaceuticals, Inc. (“Parent”) and ANIP Merger Sub INC., a wholly owned indirect subsidiary of Parent (“Merger Sub”). On September 16, 2024, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the “Merger”) effective as of the effective time of the Merger (the “Effective Time”), with the Issuer surviving as a wholly owned indirect subsidiary of Parent. At the Effective Time, each Share of the Issuer owned by the Reporting Persons immediately prior to the Effective Time was converted into the right to receive (i) $5.50 in cash, without interest (such amount, the “Closing Cash Consideration”) and (ii) one contingent value right (“CVR”) representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and Continental Stock Transfer & Trust Company (the consideration contemplated by (i) and (ii), together, the “Merger Consideration”).

In addition, pursuant to the terms of the Merger Agreement, at the Effective Time, each warrant to purchase Shares issued by the Issuer (“Warrant”) that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Warrant, the same Merger Consideration as such holder would have been entitled to receive if such holder had been, immediately prior to the Effective Time, the holder of the number of Shares then issuable upon exercise in full of such Warrant without regard to any limitations on exercise contained therein. Furthermore, at the Effective Time, each stock option granted by the Issuer to purchase Shares (each, an “Option”) that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per Share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (a) the excess, if any, of the Closing Cash Consideration over the exercise price per Share of such Option; multiplied by the number of Shares underlying such Option and (b) one CVR.

Accordingly, as a result of the Merger, the Reporting Persons no longer beneficially own any securities of the Issuer.

Items 5(a) – (c) and (e) are hereby amended and restated to read as follows:

(a), (b) Effective September 16, 2024, as a result of the Merger, each Share, Warrant and Option owned by the Reporting Persons was converted into the Merger Consideration (or portion thereof with respect to Options, as set forth in Item 4). Accordingly, the Reporting Persons no longer beneficially own any securities of the Issuer.

(c) Except as otherwise set forth in Item 4, there have been no transactions in the securities of the Issuer by the Reporting Persons during the past 60 days.

(e) As of September 16, 2024, the Reporting Persons ceased to be the beneficial owners of more than 5% of the Shares of the Issuer.

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: September 16, 2024